Incorporated in 2006, MC Toxicology Consulting (MCTOX) is a biopharmaceutical service company, specialised in early stage drug development with a focus on regulatory strategy, toxicology, pharmacology, pharmacokinetics, as well as scientific writing. MCTOX’ expertise covers the entire spectrum from small molecule drugs to biologics, Advanced Therapy Medicinal Products (ATMPs), medical devices and also cosmetics. The company also supports its clients with high-quality, hands-on operational support for the execution of non-clinical development programmes.
Clients, both small and mid-sized biotech companies and large pharma enterprises, are mainly based in Europe and North America, but also in the Middle East and Southeast Asia. Since its inception, MC Toxicology Consulting has served more than 200 clients with high-quality non-clinical development and regulatory consulting.
MCTOX is involved in the CureCN Work Packages (WP) 4 and 5. In WP4, the role of MCTOX is to prepare the research reports from the data generated in the neonatal and vector integration studies by AMC, GNT and the external collaborator ICGEB, as well to provide regulatory insights. In WP5, the role of MCTOX is to provide development and regulatory input into the vector re-administration studies performed by GNT and AMC in collaboration with GNS and the external collaborator SELB, to lead on preparation of a scientific advice meeting regarding the vector re-administration program, as well as to monitor the GLP-compliant toxicology program for vector re-administration and to supervise the report preparation.
Staff members involved
